Premium Nahrungsergänzungsmittel | artgerecht

Amyloid Accumulation – Causes, Symptoms and Treatment

Amyloid accumulation refers to the pathological buildup of misfolded proteins (amyloid) in tissues and organs, which can lead to serious organ dysfunction and disease.

Regular tips about health Regular tips about health

Things worth knowing about "Amyloid Accumulation"

Amyloid accumulation refers to the pathological buildup of misfolded proteins (amyloid) in tissues and organs, which can lead to serious organ dysfunction and disease.

What is Amyloid Accumulation?

Amyloid accumulation is the process by which amyloid fibrils – insoluble, misfolded protein aggregates – deposit in various tissues and organs throughout the body. These deposits disrupt normal tissue architecture and significantly impair organ function. The group of diseases caused by amyloid deposition is collectively known as amyloidosis. Amyloid can accumulate locally in a single organ or systemically throughout the entire body.

Causes and Pathogenesis

Amyloid accumulation occurs when certain proteins lose their normal three-dimensional structure and aggregate into insoluble fibers. The most common causes include:

Chronic inflammatory diseases (e.g., rheumatoid arthritis, Crohn disease) – leading to AA amyloidosis through deposition of serum amyloid A protein
Plasma cell disorders (e.g., multiple myeloma) – causing AL amyloidosis due to abnormal immunoglobulin light chains
Genetic mutations – causing hereditary amyloidosis, such as mutated transthyretin (ATTR amyloidosis)
Aging processes – wild-type transthyretin amyloidosis (formerly called senile systemic amyloidosis)
Neurodegeneration – in Alzheimer disease, beta-amyloid (Aß) accumulates in the brain, forming so-called senile plaques

Affected Organs and Symptoms

Symptoms vary depending on the organ affected. Amyloid accumulation can involve virtually any organ system:

Heart

Heart failure and reduced cardiac function
Cardiac arrhythmias
Shortness of breath on exertion or at rest

Kidneys

Nephrotic syndrome (massive protein loss in the urine)
Progressive kidney failure

Nervous System

Peripheral neuropathy (tingling, numbness, pain in hands and feet)
Autonomic dysfunction (e.g., orthostatic hypotension, gastrointestinal motility issues)
Cognitive impairment (in cerebral amyloid deposition, as seen in Alzheimer disease)

Liver and Spleen

Enlargement of the liver (hepatomegaly) and spleen (splenomegaly)
Impaired liver function

Other Possible Symptoms

Unexplained weight loss
Pronounced fatigue and exhaustion
Macroglossia (enlarged tongue, characteristic of AL amyloidosis)
Carpal tunnel syndrome (often an early sign of ATTR amyloidosis)

Diagnosis

Diagnosing amyloid accumulation typically requires several investigative steps:

Tissue biopsy with Congo red staining: Amyloid deposits show characteristic apple-green birefringence under polarized light – this is considered the gold standard of diagnosis
Blood and urine tests: Detection of free light chains, elevated serum amyloid A, or transthyretin mutations
Echocardiography and MRI: Assessment of cardiac function and the extent of cardiac amyloidosis
Bone scintigraphy (DPD/HMDP scan): A nuclear medicine technique particularly useful for ATTR amyloidosis
Genetic testing: To identify hereditary amyloidosis mutations

Treatment

Treatment depends on the type of amyloidosis, the organs involved, and the severity of the disease. The primary goal is to halt the further production of amyloid precursors and to preserve organ function.

AL Amyloidosis

High-dose chemotherapy, often followed by autologous stem cell transplantation
Newer agents such as daratumumab (anti-CD38 antibody) have shown promising results

AA Amyloidosis

Treatment of the underlying inflammatory condition (e.g., with biologics or colchicine)

ATTR Amyloidosis

Tafamidis: Stabilizes the transthyretin protein and slows disease progression
RNA interference therapies (e.g., patisiran, inotersen): Reduce the production of misfolded transthyretin
Liver transplantation: An option in hereditary ATTR amyloidosis, as the liver is the primary source of the mutant protein

Alzheimer-Associated Amyloid Accumulation

New anti-amyloid antibodies (e.g., lecanemab, donanemab) target the removal of beta-amyloid plaques from the brain and are currently in clinical use or under regulatory review

Supportive Measures

Symptomatic management of heart failure, kidney disease, and neuropathy
Regular follow-up to monitor organ function and disease progression

References

Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. New England Journal of Medicine. 2003;349(6):583-596.
Gertz MA. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. American Journal of Hematology. 2022;97(6):818-829.
Hawkins PN et al. Evolving landscape in the management of transthyretin amyloidosis. Annals of Medicine. 2015;47(8):625-638.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category